Hipertensión pulmonar: criterios actuales de diagnóstico y tratamiento

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Medicina Clinica

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S0025-7753(02)72461-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study ☆

  2002cited by this paper
• Recommendations on the management of pulmonary hypertension in clinical practice.

  2001cited by this paper
• BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.

  2001cited by this paper
• Guías de práctica clínica de la Sociedad Española de Cardiología en tromboembolismo e hipertensión pulmonar

  2001cited by this paper
• Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

  2001cited by this paper
• Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension

  2001cited by this paper
• Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension

  2000cited by this paper
• Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

  2000cited by this paper
• Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

  2000cited by this paper
• A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION

  2000cited by this paper
• Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene

  2000cited by this paper
• Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

  2000cited by this paper
• Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.

  2000cited by this paper
• Sildenafil in primary pulmonary hypertension.

  2000cited by this paper
• Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family

  2000cited by this paper
• Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

  2000cited by this paper
• Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial

  2000cited by this paper
• Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

  2000cited by this paper
• Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

  1999cited by this paper
• The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report--1999.

  1999cited by this paper
• The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.

  1998cited by this paper
• Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

  1998cited by this paper
• Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas.

  1998cited by this paper
• Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.

  1997cited by this paper
• Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.

  1997cited by this paper
• Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

  1996cited by this paper
• Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

  1995cited by this paper
• Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

  1995cited by this paper
• Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

  1993cited by this paper
• The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

  1992cited by this paper
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper
• Pulmonary hypertension due to toxic oil syndrome. A clinicopathologic study.

  1989cited by this paper
• Novel regulators of bone formation: molecular clones and activities.

  1988cited by this paper
• PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY

  1987cited by this paper
• The case for treatment of selected patients with primary pulmonary hypertension.

  1986cited by this paper
• Primary pulmonary hypertension: natural history and the importance of thrombosis.

  1984cited by this paper

• Comparación del efecto de dos programas de Ejercicio Físico Uno Aeróbico y otro de Contra resistencia sobre la Capacidad Funcional Cardiorrespiratoria y la Salud Mental en Pacientes con Hipertensión Pulmonar Arterial

  2013cites this paper
• Tratamiento combinado con prostaciclina intravenosa y sildenafilo en pacientes con hipertensión arterial pulmonar: descripción de 4 casos

  2004cites this paper
• Hipertensión arterial pulmonar y síndrome de Sjögren primario: una asociación infrecuente

  2004cites this paper
• Tratamiento de la hipertensión pulmonar

  2004influential citation